SCM
RADX

Stonepine Capital Management’s Radiopharm Theranostics RADX Stock Holding History

Stonepine Capital Management’s Portfolio RADX Stock Details RADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$671K Hold
51,000,000
– – 0.38% 59
2026
Q1 		$739K Buy
51,000,000
+50,837,002
+31,189% +$248M 0.3% 46
2025
Q4 		$851K Buy
+162,998
New +$868K 0.62% 41

Other funds holding RADX

HSBC Holdings
HSBC Holdings London, United Kingdom $239B AUM 42.32% 1-Year Est. Return
RP
Regal Partners Sydney, NSW, Australia $1.81B AUM 52.11% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Stonepine Capital Management's RADX Position: Q2 2026 in Review

Stonepine Capital Management held its Radiopharm Theranostics (RADX) position steady in Q2 2026 at 51,000,000 shares worth $671K. The position accounts for 0.38% of the portfolio, ranked #59.

Stonepine Capital Management first reported a position in RADX in Q4 2025 and has held it in 3 quarters since. The position peaked at $851K in Q4 2025. 7 funds tracked by Wall St. Rank hold RADX as of Q2 2026.

  • Stonepine Capital Management held 51,000,000 shares of Radiopharm Theranostics worth $671K as of Q2 2026.
  • Stonepine Capital Management left its Radiopharm Theranostics share count unchanged in Q2 2026.
  • Radiopharm Theranostics made up 0.38% of Stonepine Capital Management's portfolio in Q2 2026, its #59 holding.
  • Stonepine Capital Management first reported a position in Radiopharm Theranostics in Q4 2025 and has held it in 3 quarters since.
  • Stonepine Capital Management's Radiopharm Theranostics position peaked at $851K in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Radiopharm Theranostics as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.